drugset
drugset / Trial / NCT01239706

Safety Study of Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Traumatic Brain Injury: Dosing Tier 1

NCT01239706 ↗

Phase 2 Unknown 10 enrolled University of Calgary Stem Cell Therapeutics Corp. · collab
NaSingle-groupOpen-labelTreatment

Summary

Prospective, Open Label, Cohort Study in Traumatic Brain Injury Patients. The goal of this study is to assess the safety of NTx®-265. NTx®-265 will be administered over 9 days, and patients will be followed for an additional 6 months.

Timeline

Start
2010-11
Primary completion
2012-06
Completion
2012-06

Drugs

EvaluationDrugModalityDoseRoute
Subject epoetin alfa Protein / enzyme biologic 4000 iu —
Subject human chorionic gonadotropin Protein / enzyme biologic 10000 iu —

Indications

traumatic brain injury